Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication -: A randomized controlled trial (MACLOR study)

被引:93
作者
Treiber, G
Wittig, J
Ammon, S
Walker, S
van Doorn, LJ
Klotz, U
机构
[1] Robert Bosch Krankenhaus, Dept Gastroenterol, Stuttgart, Germany
[2] Hosp Bietigheim, Dept Gastroenterol, Bietigheim, Germany
[3] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[4] R DeGraaf Grp, SSDZ, Delft Diagnost Ctr, Delft, Netherlands
关键词
D O I
10.1001/archinte.162.2.153
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Short-term therapies for eradicating Helicobacter pylori in selected patients might offer advantages in terms of costs, compliance, and adverse effects in contrast to standard I-week triple therapy. Methods: To determine eradication success and influencing factors in a new short-term quadruple therapy, a total of 243 patients positive for H pylori were randomly assigned to I of 3 regimens according to age, smoking status, and diagnosis: a 5-day treatment with 3 antibiotics (amoxicillin, 1 g twice daily [bid]; clarithromycin, 250 mg bid; and metronidazole, 400 mg bid) and lansoprazole (30 mg bid [L5; reference treatment]) or ranitidine hydrochloride (300 mg bid [R5]), or the same 3-day antibiotic-lansoprazole combination (L3) with a 2-day pretreatment with lansoprazole. Results: A total of 234 patients completed the study. On an intention-to-treat basis, overall eradication of H pylori was confirmed in 86.4%: 89.2% in the L5 group vs 81.2% in the L3 group vs 88.8% in the R5 group; differences were not significant. Multiple logistic regression analysis showed that younger age (<55 years; P=.03), history of peptic ulcer disease (P=.04), smoking (P=.03), metronidazole resistance (P=.003), low ranitidine trough serum concentrations (P=.005), cytotoxin-associated. gene A-negative strains in peptic ulcer disease (P=.04), and outer inflammatory protein A-positive strains (P=.02) were associated with eradication failure. Conclusions: This new quadruple H pylori eradication regimen is efficacious, safe, well tolerated, and cost saving, and may be a treatment option for patients older than 55 years with no history of peptic ulcer disease. Furthermore, strains that are sensitive to all antibiotics, cytotoxin-associated gene A-positive, and outer inflammatory protein A-negative could be suitable for short-term quadruple therapy. Patients with an unfavorable combination of characteristics should be treated for a minimum of 7 days.
引用
收藏
页码:153 / 160
页数:8
相关论文
共 50 条
[1]  
Ammon S, 2000, ALIMENT PHARM THERAP, V14, P759
[2]   Use of immunoblot assay to define serum antibody patterns associated with Helicobacter pylori infection and with H-pylori-related ulcers [J].
Aucher, P ;
Petit, ML ;
Mannant, PR ;
Pezennec, L ;
Babin, P ;
Fauchere, JL .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (04) :931-936
[3]  
Calvet X, 2000, ALIMENT PHARM THER, V14, P603
[4]   Helicobacter pylori-positive duodenal ulcer:: three-day antibiotic eradication regimen [J].
Catalano, F ;
Branciforte, G ;
Catanzaro, R ;
Cipolla, R ;
Bentivegna, C ;
Brogna, A .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) :1329-1334
[5]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[6]  
CUTLER AF, 1993, AM J GASTROENTEROL, V88, P505
[7]   Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice [J].
Goddard, AF ;
Jessa, MJ ;
Barrett, DA ;
Shaw, PN ;
Idstrom, JP ;
Cederberg, C ;
Spiller, RC .
GASTROENTEROLOGY, 1996, 111 (02) :358-367
[8]   Therapy of Helicobacter pylori:: Current status and issues [J].
Graham, DY .
GASTROENTEROLOGY, 2000, 118 (02) :S2-S8
[9]  
Gschwantler M, 1999, ALIMENT PHARM THER, V13, P1063
[10]   EFFECT OF OMEPRAZOLE ON CONCENTRATIONS OF CLARITHROMYCIN IN PLASMA AND GASTRIC TISSUE AT STEADY-STATE [J].
GUSTAVSON, LE ;
KAISER, JF ;
EDMONDS, AL ;
LOCKE, CS ;
DEBARTOLO, ML ;
SCHNECK, DW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (09) :2078-2083